Price Forecast:

Bullish Case: Sangamo's potential FDA accelerated approval for its Fabry gene therapy could catalyze a significant price rebound, aligning with favorable analyst sentiment and strategic partnerships.

Bearish Case: Continued operational struggles and historical revenue declines raise concerns about further price depreciation, compounded by high implied volatility reflecting market uncertainty.

Potential Outcomes:

1. 30%: Successful FDA approval driving prices upward.

2. 40%: Continued flat performance with no growth.

3. 20%: Further decline in value due to operational issues.

4. 10%: Strategic partnership leading to market recovery.

Trading Oracle: Consider a bearish long volatility strategy by buying 2 $1.50 put options and selling 3 $1.00 puts to exploit volatility while maintaining downside protection. This setup benefits from potential price dips while capitalizing on high implied volatility.

October 27, 2024